Compare Home Depot Inc (HD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Organon & Co. Common Stock — how do they compare? Home Depot Inc trades at $298.67 (market cap $293.24B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Home Depot Inc is far larger — about 81× Organon & Co. Common Stock's market cap, and Home Depot Inc pays the higher dividend (3.17%). Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Organon & Co. Common Stock for 0 Days on average.
| HD | OGN | |
|---|---|---|
Market Cap | $293.24B | $3.62B |
Volume | 4,521,013 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $13.81 |
52-Week Low | $281.15 | $5.70 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $353.72B | $11.04B |
Dividend Yield | 3.17% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $293.92, up 1.14% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 33.21% gross margins and 104.3% ROE, though net margins have declined from 10.87% in 2022 to 8.41% currently. Analyst consensus remains bullish with a $379.93 price target, representing 29% upside potential from current levels. Recent institutional activity shows mixed sentiment with both acquisitions and reductions in holdings.
HD faces near-term headwinds from weakening big-ticket demand and margin pressure, but strong Pro business and housing tailwinds support long-term growth. The stock's current valuation at 20.57 P/E appears reasonable relative to historical levels. Key risks include rising mortgage rates impacting housing activity and competitive pressures in home improvement retail.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
